Safety and Tolerability of I-040302 in Children and Young Adults With Solitary Bone Cysts

Kuros Biosciences

Status and phase: Withdrawn; Phase 2

Conditions: Bone Cysts

Treatments: Other: Standard of Care; Drug: I-040302

Study type: Interventional

Funder types: Industry

Identifiers

NCT00459641

CS I-040302/01

Details and patient eligibility

About

This is a randomised, controlled, open-label study of a single intralesional administration of I-040302 or a single bone marrow aspirate or a single steroid injection (methylprednisolone). Subjects will undergo screening with X-ray and magnetic resonance imaging (MRI) in the diagnosis of a solitary bone cyst.

Sex: All

Ages: 6 to 16 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Subjects 6 - 16 years of age

2. Diagnostic evidence of unicameral bone cysts based on one or more of a combination of any of the following methods:

   • Cyst fluid examination
   • Plain radiographs
   • MRI

3. Subjects with the following types of cysts:

   • Intact cysts that are either growing or at risk of fracture, requiring surgical intervention
   • Persistence of a cyst cavity following cyst fracture that has received conservative treatment/s to repair the fracture
   • Persistence of a cyst cavity despite repeated interventions

4. Subjects with bone cyst volumes < 30 mL

5. Subjects must be appropriately communicative to verbalise pain.

6. Subjects must be able to understand and be willing to comply with the protocol procedures.

7. Subjects who have provided written informed consent to participate in the study

8. The legally authorised representative of the child must give written informed consent after the child has agreed to participate in the study.

Exclusion criteria

1. A history of/or presence of active cancer
2. Family history of retinoblastoma
3. Indication of aneurysmal bone cyst on MRI, cyst aspiration or histology
4. Possible presence of osteosarcoma or uncertain histology
5. Systemic or localised infection at time of surgery
6. Evidence of immune-suppression
7. Evidence of hypercalcemia
8. Cyst volume > 30 mL
9. Fracture present in the cortical bone surrounding the cyst
10. Evidence of rapid venous drainage from the cyst determined by rapid disappearance of X-ray contrast medium during the surgical process.
11. Suspected or known evidence of allergic reactions towards any of the components of I-040302
12. Known clinically significant organ or systemic diseases such that, in the opinion of the investigator, the significance of the disease will compromise the subject's participation in the study
13. Pregnant or lactating females
14. Participation in another clinical trial within 3 months prior to trial start

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

0 participants in 2 patient groups

1

Experimental group

Description:

I-040302 doses of up to 1 mg, 2 mg or 4 mg of TGplPTH1-34

Treatment:

Drug: I-040302

2

Active Comparator group

Description:

Standard of care (bone marrow aspirate or steroids)

Treatment:

Other: Standard of Care